Linda K. Hendricks MD

Central Georgia Cancer Care, PC - Macon

Education and Training

Specialty and Certification

Medical Oncology / Board Certified

Clinical Trial Cancer Types

Breast Cancer, Eye Cancer, Lung Cancer, Lymphoma, Multiple Primaries, Non-Hodgkin Lymphoma, Oral Cancer, Prostate Cancer , Solid Tumor

Affiliations

Georgia CORE Peyton Anderson Cancer Center Navicent Health
Medical Center of Central Georgia Houston Medical Center
Accelerated Community Oncology Research Network (ACORN) University of Alabama

Active Clinical Trial Sites in Georgia



Central Georgia Cancer Care, PC - Warner Robins

114 Sutherland Drive
Suite C-1
Warner Robins, GA 31088
478-287-6144 (p)
www.centralGeorgiacancercare.com

driving directions





Peyton Anderson Cancer Center, Navicent Health

800 1st Street
Macon, GA 31201
478-633-2152 (p)
478-633-8894 (f)
www.navicenthealth.org

driving directions

Clinical Trials
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy vs. Observation in Patients with Residual Triple-Negative Basal-like Breast Cancer following Neoadjuvant Chemotherapy
Cancer Type: Breast Cancer

Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Cancer Type: Breast Cancer

EAY131: Molecular Analysis for Therapy Choice (NCI-MATCH)
Cancer Type: Eye Cancer

Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
Cancer Type: Lung Cancer

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Cancer Type: Lung Cancer

A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Cancer Type: Lung Cancer

EAY131: Molecular Analysis for Therapy Choice (NCI-MATCH)
Cancer Type: Lymphoma

EAY131: Molecular Analysis for Therapy Choice (NCI-MATCH)
Cancer Type: Multiple Primaries

EAY131: Molecular Analysis for Therapy Choice (NCI-MATCH)
Cancer Type: Non-Hodgkin Lymphoma

Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered With Concurrent Cisplatin Versus Docetaxel Versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck
Cancer Type: Oral Cancer

Phase III Randomized Study of Androgen-Deprivation Therapy and High-Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Patients With Unfavorable Intermediate- or Favorable High-Risk Prostate Cancer
Cancer Type: Prostate Cancer

EAY131: Molecular Analysis for Therapy Choice (NCI-MATCH)
Cancer Type: Solid Tumor

EAY131: Molecular Analysis for Therapy Choice (NCI-MATCH)
Cancer Type: Unknown Primary

Active Clinical Trial Site Locations: